Aliskiren + Ramipril + Matching placebo to Aliskiren + Matching placebo to Ramipril
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Essential Hypertension
Conditions
Essential Hypertension
Trial Timeline
Nov 1, 2009 → Jan 1, 2011
NCT ID
NCT01042392About Aliskiren + Ramipril + Matching placebo to Aliskiren + Matching placebo to Ramipril
Aliskiren + Ramipril + Matching placebo to Aliskiren + Matching placebo to Ramipril is a approved stage product being developed by Novartis for Essential Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT01042392. Target conditions include Essential Hypertension.
What happened to similar drugs?
14 of 20 similar drugs in Essential Hypertension were approved
Approved (14) Terminated (2) Active (6)
✅Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg + Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mgYuhanApproved
✅olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessaryDaiichi SankyoApproved
✅olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessaryDaiichi SankyoApproved
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01042392 | Approved | Completed |
Competing Products
20 competing products in Essential Hypertension